Skip to main content

The Globe and Mail

Aggressive Valeant plans $1.5-billion share buyback

Valeant’s head office in Montreal.

Ryan Remiorz/The Canadian Press

Valeant Pharmaceuticals International Inc.'s board has approved a new share buyback program for up to $1.5-billion.

Montreal-based Valeant, Canada's largest publicly listed drug manufacturer, said on Wednesday the securities repurchase program covers convertible notes, senior notes, common shares and/or other debt or shares that could be issued before the end of the program.

The new plan replaces the company's former program, which expired on Nov. 14, 2013.

Story continues below advertisement

Under the previous program Valeant bought 507,957 common shares for a total value of $35.7-million, the company said.

Valeant said that, under the new plan, it may buy up to 16.64 million common shares, representing about 5 per cent of the issued and outstanding shares.

The company has grown by leaps and bounds over the past several years through a flurry of acquisitions.

Earlier this month, chief executive officer Michael Pearson said the goal is to become one of the world's top five pharmaceutical companies by market capitalization by the end of 2016, mainly via acquisitions.

Valeant would need a market capitalization of about $150-billion (U.S.) to break into the top five, he said.

The company's current value is in the $40-billion range, putting it in the top 15.

Last year alone, Valeant completed 25 acquisitions, including the purchase of contact lens maker Bausch + Lomb Holdings Inc. for $8.7-billion.

Story continues below advertisement

Report an error Licensing Options
About the Author
Quebec Business Correspondent

Bertrand has been covering Quebec business and finance since 2000. Before joining The Globe and Mail in 2000, he was the Toronto-based national business correspondent for Southam News. He has a B.A. from McGill University and a Bachelor of Applied Arts from Ryerson. More

Comments

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨

Combined Shape Created with Sketch.

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at privacy@globeandmail.com.